Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatoid Arthritis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatoid Arthritis
    Anti-TNF Treatment Does Not Increase Cancer Risk in Patients With RA - (DGNews)
    TopAbstracts in Rheumatoid Arthritis 10/29/2009 - (DGNews)
    Tocilizumab Plus Methotrexate Provides Sustained Benefits in Patients With RA: Presented at ACR/ARHP - (DGDispatch)
    Novel JAK Inhibitor Shows Promise as an Effective Treatment for Rheumatoid Arthritis: Presented at ACR/ARHP - (DGDispatch)
    Oral Syk Kinase Inhibitor Improves Response Rates in RA Patients on Methotrexate: Presented at ACR/ARHP - (DGDispatch)

    News archive

     Recent webcasts/CME - Rheumatoid Arthritis
      Comorbidity in Patients with Rheumatoid Arthritis: What are the Real Concerns?
      Advances in Basic Science
      Quantitatively-Driven Management of Rheumatoid Arthritis
      Cancer, Liver, Infections, Cardiovascular Disease, and other Biologic Agents
      Rheumatoid Arthritis: Clinical Aspects, Outcomes, and Measures

      Webcasts/CME archive

       Recent cases - Rheumatoid Arthritis
        Mesenteric Rheumatoid Nodules Masquerading as an Intra-Abdominal Malignancy: A Case Report and Review of the Literature
        Co-Existence of Acute Myeloid Leukemia with Multilineage Dysplasia and Epstein-Barr Virus-Associated T-Cell Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis
        Patient with Hepatitis B and Rheumatoid Arthritis
        Complete Heart Block and Severe Aortic Stenosis in a Patient with Rheumatoid Arthtritis: A Case Report
        Limited Wegener's Granulomatosis Presenting as Lung Nodules in a Patient with Rheumatoid Arthritis: A Case Report

        Cases archive
          




        my personal edition > rheumatoid arthritis > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Methotrexate Long-Time Favourite Rheumatoid Arthritis Therapy

        A DGReview of :"The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses."
        Rheumatology

        12/18/2002
        By Anne MacLennan


        A long-term comparison of more than 1,300 consecutive courses of disease-modifying anti-rheumatic drugs (DMARDs) has found methotrexate traditionally the most commonly used for rheumatoid arthritis (RA).

        Moreover, this agent came to be used increasingly as first therapy in newly diagnosed RA, report Drs D Aletaha and J S Smolen from the University of Vienna and Lainz Hospital, Vienna, Austria.

        Sequential use of DMARDs is typical RA therapy. Authors of this single-centre study sought to reveal the changing patterns of use of traditional DMARDs over two decades before newer ones emerged.

        Researchers followed 593 RA patients from their first clinic visit through the course of their disease, analysing more than 2,300 patient years of therapy for efficacy and duration of consecutive DMARDs therapy. Of the 593 patients, 222 received their first such therapy at this clinic.

        Prior to 1985, between 65 percent and 90 percent of initial DMARDs were gold compounds. However, their use decreased continuously after that.

        While antimalarial (AM) drugs were important initial DMARDs in new patients at all times, sulphasalazine (SSZ) and methotrexate (MTX) gained increasing significance after 1985. Indeed, the first DMARD was MTX in up to 29 percent of new patients.

        Penicillamine (DPA), azathioprine (AZP), cyclosporin (CyA) and combination therapies were not used initially, but rather were reserved for the later course of the disease.

        This investigation found there were no gender, age or rheumatoid factor differences among patients receiving different DMARDs.

        However, baseline acute-phase response was higher in patients treated with MTX versus SSZ or AM, suggesting MTX was used preferentially in patients with high disease activity, the authors note. On the other hand, once AM or SSZ had been discontinued, MTX was the most common subsequent DMARD.

        Comparison of first DMARDs with subsequent ones indicates first DMARDs were more effective: the acute-phase response decreased most prominently during first therapies, and retention rates were significantly longer for first versus subsequent therapies (median of 24.5 months for first and 18.6 months for fourth or subsequent therapies). Thus, MTX was most commonly used and was used increasingly as first therapy in new RA.

        While patients with high disease activity were given MTX therapy more often than other DMARDs, those with low activity were more likely to receive SSZ or AM and MTX on failure of these drugs.

        Finally, first DMARDs in new patients were retained longer than subsequent DMARDs, evidently because they are more effective, these authors conclude.
        Rheumatology (Oxford) 2002;41(12):1367-74. "The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses."

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send